Cardiff Oncology, Inc. is a clinical-stage biotechnology company that develops novel therapies using PLK1 inhibition for various types of cancers. The company will be holding a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT in San Diego to release their financial results for the first quarter ended March 31, 2024.
Interested individuals can listen to the conference call and webcast using the webcast link in the “Investors” section of Cardiff Oncology’s website. A replay of the call will be available in the investor relations section of the website after the call is completed.
Cardiff Oncology’s lead asset is onvansertib, a PLK1 inhibitor currently undergoing evaluation in combination with standard-of-care therapeutics for various indications such as RAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. The company’s development strategy focuses on targeting tumor vulnerabilities to overcome treatment resistance and deliver better clinical outcomes. More information can be found on Cardiff Oncology’s website.
For further information, individuals can contact Cardiff Oncology’s Chief Financial Officer, James Levine, at 858-952-7670 or Kiki Patel, PharmD at Gilmartin Group for investors or Grace Spencer at Taft Communications for media inquiries
